Home / Business and Economy / UCB Buys Candid Therapeutics for Up to $2.2 Billion
UCB Buys Candid Therapeutics for Up to $2.2 Billion
4 May
Summary
- UCB acquired Candid Therapeutics for a potential $2.2 billion.
- The deal includes $2 billion in upfront payments.
- Candid Therapeutics focuses on autoimmune disease treatments.
Belgian biopharmaceutical firm UCB has entered into an agreement to purchase Candid Therapeutics, a privately-held company focused on autoimmune disease treatments. The acquisition is valued at a potential maximum of $2.2 billion. This significant deal comprises upfront payments totaling $2 billion, with the possibility of an additional $200 million contingent on future development milestones. Candid Therapeutics, based in California, has been developing novel therapeutic approaches for various autoimmune conditions. The integration of Candid Therapeutics is expected to enhance UCB's portfolio and research capabilities in the highly competitive biopharmaceutical landscape, particularly in the area of autoimmune disorders. This move underscores UCB's commitment to advancing treatments for patients with unmet medical needs in autoimmune diseases.
